HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

NCT03780634 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: HAIC
DRUG: PD-1 antibody
DRUG: Sorafenib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]